Immunonutrition supplements before surgery for esophageal, stomach and pancreatic cancer
Tests an immunonutrition supplement before surgery in adults with upper digestive tract cancer.
Key facts
- Who runs it
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
- Where
- Madrid, SpainSee the site
- Trial code
- Registry title
- Immunonutrition for Surgical Prehabilitation of Patients With Upper GI Cancer
- Status
- Enrolling by invitation
- People taking part
- 110 people, planned
- Started
- 1 Jan 2026
- Expected to end
- 1 Jul 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Oral nutritional supplements with immunonutrition (enriched with arginine, nucleotides, vitamin D and omega-3-fatty acid)
- Standart of care
- Record updated
- 20 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who are going to have surgery for upper GI cancer (stomach, esophagus or pancreas). It compares a special nutrition supplement with standard supplementation.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Upper GI cancer (gastric, esophageal or pancreatic) that can be treated with surgery
- Earlier treatment
- Cannot have taken nutritional supplements before
Main reasons for not taking part
- Upper GI cancer that is not treated with surgery
- End-stage liver or kidney disease
- Emergency surgery
- Cannot take food by mouth (for example swallowing problems, narrowing of the esophagus or pylorus)
- HIV infection, pregnancy, intestinal obstruction, or active uncontrolled infection
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Patients eligible for upper GI cancer surgery
Who cannot take part
- Emergency surgery
- Previous nutritional supplements
- Non-surgical upper GI cancer
- End-stage liver o kidney disease
- Hypersensitivity to arginine, omega-3, or nucleotides
- HIV infection
- Active uncontrolled infection
- Dementia, advanced degenerative neurological disease
- Inability for oral nutrition (dysphagia, esophageal/pyloric stenosis)
- Pregnancy
- Intestinal obstruction
Where in Spain
- Hospital Universitario Ramón y CajalMadrid, SpainNo longer taking part
About the trial
What the trial wants to find out
Perioperative immunonutrition has been proposed as a strategy to modulate the inflammatory response and improve outcomes after upper GI surgery. However, clinical evidence is heterogeneous, and there are few studies that integrate morbidity outcomes with objective measures of body composition using computed tomography (CT). The objective was to compare immunonutrition versus standard enteral supplementation in surgically treated patients with upper GI cancer (gastric, esophageal, pancreatic), evaluating postoperativecomplications and changes in body composition.
The 2 groups in the trial
- ControlExisting treatment, for comparison
Standard oral nutritional supplements
Treatment: Standart of care
- ImmunonutritionTreatment being tested
Oral nutritional supplements with immunonutrition
Treatment: Oral nutritional supplements with immunonutrition (enriched with arginine, nucleotides, vitamin D and omega-3-fatty acid)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Nutritional Therapy in the Surgical Prehabilitation of Patients With Esophageal, Gastric, and Pancreatic Cancer to Assess the Reduction of Postoperative Complications and the Maintenance of Muscle Mass.
- Plain-language title
- Immunonutrition supplements before surgery for esophageal, stomach and pancreatic cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 20 October 2026